# EDGAR Filing Document

**Accession Number:** 0001522767
**File Stem:** 0001522767-23-000037
**Filing Date:** 2023-3
**Character Count:** 7471
**Document Hash:** 54481a5e64a0b8eac68e6cf50711034a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001522767-23-000037.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001522767-23-000037

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230307

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Levine Jon R
- **CENTRAL INDEX KEY:** 0001789645

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54433
- **FILM NUMBER:** 23731629

**MAIL ADDRESS:**
- **STREET 1:** C/O MARIMED INC.
- **STREET 2:** 10 OCEANA WAY
- **CITY:** NORWOOD
- **STATE:** MA
- **ZIP:** 02062
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MARIMED INC.
- **CENTRAL INDEX KEY:** 0001522767
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 274672745
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10 OCEANA WAY
- **STREET 2:** 2ND FLOOR
- **CITY:** NORWOOD
- **STATE:** MA
- **ZIP:** 02062
- **BUSINESS PHONE:** 617-795-5940

**MAIL ADDRESS:**
- **STREET 1:** 10 OCEANA WAY
- **STREET 2:** 2ND FLOOR
- **CITY:** NORWOOD
- **STATE:** MA
- **ZIP:** 02062

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WORLDS ONLINE INC.
- **DATE OF NAME CHANGE:** 20110608

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Levine Jon R<br><sub>(Last) (First) (Middle)</sub><br>C/O MARIMED INC.<br>10 OCEANA WAY<br><sub>(Street)</sub><br>NORWOOD,, MA 02062<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>MARIMED INC. [ MRMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common stock |  |  |  |  |  |  |  | 20012087 | D |  |
| Common stock |  |  |  |  |  |  |  | 6684640 | I | By the Jon Levine Family Trust<sup>(1)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units (RSU) | <sup>(2)</sup> | 2023-03-07 |  | A |  | 140000 |  | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock, par value $.001 per share | 140000.0 | $0 | 140000 | D |  |
| Restricted Stock Units (RSU) | <sup>(2)</sup> |  |  |  |  |  |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock, par value $.001 per share | 833333.0 |  | 833333 | D |  |
| Option to buy common stock | $0.898 |  |  |  |  |  |  | <sup>(5)</sup> | 2026-10-01 | Common Stock, par value $.001 per share | 5000000.0 |  | 5000000 | D |  |
| Option to buy common stock | $0.88 |  |  |  |  |  |  | <sup>(5)</sup> | 2026-07-09 | Common Stock, par value $.001 per share | 5000000.0 |  | 5000000 | D |  |

---

### Footnotes:

(1) These shares are held in trust for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

(2) The RSUs were granted to the Reporting person in accordance with rule 16b-3(d) of the Securities Exchange Act of 1934, as amended.  Each RSU represents a contingent right to receive one share of the Issuer's common stock.  RSUs convert to common stock on a one-for-one basis.

(3) The RSUs vest over a three year period of which 46,667 RSUs will vest on March 7, 2024 and thereafter, 23,333 RSUs will vest every succeeding six (6) months through March 7, 2026, on each of September 7th and March 7th, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

(4) The RSUs vest over a three year period in equal one-sixth installments every six months following the October 27, 2022 grant date, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

(5) Immediately.

**Signature:** /s/ Jon R. Levine  
**Date:** 2023-03-13

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**